Core Insights - Eli Lilly is positioned to potentially become the first trillion-dollar pharmaceutical company, with a current market cap of $800 billion, while Berkshire Hathaway has a market cap of just over $1 trillion [2][3]. Eli Lilly's Growth Prospects - Eli Lilly is a leader in the rapidly growing weight management drug market, particularly with its product tirzepatide (Zepbound), which is driving significant sales growth [3]. - The company is also pursuing regulatory approval for orforglipron, an oral GLP-1 medication for weight management, which could attract patients averse to injections [4]. - Eli Lilly is developing retatrutide, which mimics the action of three gut hormones and has shown strong efficacy in phase 2 studies, potentially revolutionizing the GLP-1 space [6]. Berkshire Hathaway's Challenges - Berkshire Hathaway faces uncertainty regarding its long-term future as Warren Buffett steps down as CEO, leading to investor concerns about the new leadership under Greg Abel [7]. - The company's largest holding, Apple, is encountering challenges such as significant tariffs and competition in the AI market, which may hinder Berkshire's performance in the near term [9]. - Despite these challenges, Berkshire Hathaway's diversification and investment philosophy may still make it a viable long-term investment, though patience may be required [10].